Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Array BioPharma (ARRY) PT Raised to $36 at Guggenheim
May 7, 2019 12:49 PM EDTGuggenheim analyst Michael Schmidt raised the price target on Array BioPharma (NASDAQ: ARRY) to $36.00 (from $35.00) while maintaining a Buy rating.
strong sales indicated additional upside potential in Melanoma... MoreArray Biopharma (ARRY) Tops Q3 EPS by 3c
May 7, 2019 8:04 AM EDTArray Biopharma (NASDAQ: ARRY) reported Q3 EPS of ($0.17), $0.03 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $64.7 million versus the consensus estimate of $54.04 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
... More